ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.35 HKD | -2.90% |
|
-1.18% | -20.99% |
| 05-28 | Hong Kong Stocks Stayed Flat Despite Shanghai’s Property Cuts, Beijing’s Huge Investment Plan | MT |
| 05-28 | Alibaba Health Shares Rise on Earnings Beat | DJ |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 90,747 | 142,817 | 249,927 | 55,562 | 67,140 | 51,577 | - | - |
| Enterprise Value (EV) 1 | 90,430 | 140,292 | 238,291 | 55,562 | 56,300 | 47,219 | 40,061 | 37,834 |
| P/E ratio | -1,048 x | -19,731 x | 708 x | -209 x | 126 x | 46.8 x | 29.2 x | 24.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.8 x | 14.9 x | 16.1 x | 2.7 x | 2.51 x | 1.75 x | 1.65 x | 1.4 x |
| EV / Revenue | 17.7 x | 14.6 x | 15.4 x | 2.7 x | 2.1 x | 1.75 x | 1.28 x | 1.02 x |
| EV / EBITDA | -3,321 x | -2,546 x | 529 x | -53.7 x | 1,763 x | 72.6 x | 25.9 x | 19 x |
| EV / FCF | 232 x | 246 x | 246 x | 136 x | 225 x | 41 x | 21.9 x | 16.2 x |
| FCF Yield | 0.43% | 0.41% | 0.41% | 0.74% | 0.44% | 2.44% | 4.56% | 6.19% |
| Price to Book | 30.7 x | 26.8 x | 17.2 x | 3.93 x | 4.43 x | 2.87 x | 3 x | 2.63 x |
| Nbr of stocks (in thousands) | 11,700,591 | 12,063,834 | 13,477,663 | 13,507,505 | 13,511,061 | 16,081,435 | - | - |
| Reference price 2 | 7.756 | 11.84 | 18.54 | 4.113 | 4.969 | 3.207 | 3.207 | 3.207 |
| Announcement Date | 19-05-16 | 20-05-27 | 21-05-25 | 22-05-25 | 23-05-23 | 24-05-27 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,096 | 9,596 | 15,518 | 20,578 | 26,763 | 27,027 | 31,266 | 36,934 |
| EBITDA 1 | -27.23 | -55.1 | 450.2 | -1,034 | 31.93 | 559.8 | 1,545 | 1,992 |
| EBIT 1 | -31.22 | -62.41 | 442.1 | -1,094 | -31.79 | 640.2 | 1,522 | 1,871 |
| Operating Margin | -0.61% | -0.65% | 2.85% | -5.32% | -0.12% | 2.37% | 4.87% | 5.07% |
| Earnings before Tax (EBT) 1 | -60.83 | 9.094 | 401.2 | -252.5 | 551 | 939.4 | 1,797 | 2,210 |
| Net income 1 | -81.95 | -6.586 | 348.6 | -265.6 | 533.4 | 883.5 | 1,588 | 1,851 |
| Net margin | -1.61% | -0.07% | 2.25% | -1.29% | 1.99% | 3.27% | 5.08% | 5.01% |
| EPS 2 | -0.007400 | -0.000600 | 0.0262 | -0.0197 | 0.0394 | 0.0627 | 0.1098 | 0.1333 |
| Free Cash Flow 1 | 390.3 | 570.1 | 967.4 | 409.4 | 250.1 | 991.6 | 1,829 | 2,343 |
| FCF margin | 7.66% | 5.94% | 6.23% | 1.99% | 0.93% | 3.48% | 5.85% | 6.34% |
| FCF Conversion (EBITDA) | - | - | 214.88% | - | 783.16% | 177.14% | 118.35% | 117.6% |
| FCF Conversion (Net income) | - | - | 277.52% | - | 46.88% | 129.39% | 115.18% | 126.55% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 19-05-16 | 20-05-27 | 21-05-25 | 22-05-25 | 23-05-23 | 24-05-27 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,358 | 11,220 | 11,501 | 15,262 | 12,956 | 14,071 | 14,605 | 16,586 |
| EBITDA | - | - | - | - | - | - | 555 | 865 |
| EBIT 1 | -204.7 | - | -30.05 | -1.738 | 261.6 | 378.5 | 650.4 | 939.3 |
| Operating Margin | -2.19% | - | -0.26% | -0.01% | 2.02% | 2.69% | 4.45% | 5.66% |
| Earnings before Tax (EBT) 1 | - | - | 174 | - | 481.3 | 458.1 | 677 | 993 |
| Net income 1 | - | - | 160.7 | 372.7 | 445.9 | 437.6 | 643 | 943 |
| Net margin | - | - | 1.4% | 2.44% | 3.44% | 3.11% | 4.4% | 5.69% |
| EPS 2 | - | - | 0.0100 | 0.0275 | 0.0329 | 0.0298 | 0.0550 | 0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-24 | 22-05-25 | 22-11-28 | 23-05-23 | 23-11-28 | 24-05-27 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 317 | 2,525 | 11,637 | - | 10,839 | 10,911 | 11,516 | 13,743 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 390 | 570 | 967 | 409 | 250 | 992 | 1,829 | 2,343 |
| ROE (net income / shareholders' equity) | -3.05% | 6.48% | 6.44% | -1.87% | 3.64% | 5.44% | 10.7% | 11% |
| ROA (Net income/ Total Assets) | -1.8% | -0.16% | 4.93% | -1.44% | 2.67% | 3.66% | 7.54% | 7.7% |
| Assets 1 | 4,546 | 4,032 | 7,078 | 18,471 | 19,975 | 20,962 | 21,069 | 24,044 |
| Book Value Per Share 2 | 0.2500 | 0.4400 | 1.080 | 1.050 | 1.120 | 1.120 | 1.070 | 1.220 |
| Cash Flow per Share 2 | 0.0400 | 0.0500 | 0.0800 | - | 0.0200 | 0.0700 | 0.1100 | 0.1600 |
| Capex 1 | 6.1 | 13.5 | 17.1 | 14.9 | 5.61 | 17.8 | 17 | 17 |
| Capex / Sales | 0.12% | 0.14% | 0.11% | 0.07% | 0.02% | 0.06% | 0.05% | 0.05% |
| Announcement Date | 19-05-16 | 20-05-27 | 21-05-25 | 22-05-25 | 23-05-23 | 24-05-27 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
3.207
CNY
Average target price
4.889
CNY
Spread / Average Target
+52.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.99% | 7.11B | |
| -39.07% | 13.73B | |
| -41.82% | 9.46B | |
| -7.91% | 5.88B | |
| +78.71% | 4.79B | |
| -4.38% | 4.54B | |
| -21.90% | 4.35B | |
| +3.97% | 4.44B | |
| -16.91% | 2.64B | |
| -8.43% | 2.63B |
- Stock Market
- Equities
- 241 Stock
- Financials Alibaba Health Information Technology Limited
